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Abstract: Long-term clinical outcomes in patients with acute myocardial infarction (AMI) and
prediabetes or diabetes who received ß-blockers (BB) and renin–angiotensin system inhibitor
(RASI) therapy after successful newer-generation drug-eluting stent (DES) implantation are limited.
We compared the two-year clinical outcomes in such patients. A total of 9466 patients with AMI in the
Korea AMI Registry were classified into six groups according to their glycemic status and presence
or absence of BB + RASI therapy: normoglycemia and BB + RASI users (n = 2217) or nonusers
(n = 243), prediabetes and BB + RASI users (n = 2601) or nonusers (n = 306), and diabetes and BB
+ RASI users (n = 3682) or nonusers (n = 417). The primary endpoint was major adverse cardiac
events (MACEs) defined as all-cause death, recurrent myocardial infarction (Re-MI), or any repeat
revascularization, and the secondary endpoint was the cumulative incidence of hospitalization for
heart failure (HHF). In patients with BB + RASI, despite similar primary and secondary clinical points
between the prediabetes and diabetes groups, the cumulative incidence of Re-MI (adjusted hazard
ratio: 1.660; 95% confidence interval: 1.000–2.755; p = 0.020) was higher in the diabetes group than
in the prediabetes group. In all three different glycemic groups, BB + RASI users showed reduced
MACEs, cardiac death, and HHF compared to those of BB + RASI nonusers. In this retrospective
observational registry study, BB + RASI therapy showed comparable clinical outcomes except for
Re-MI between prediabetes and diabetes in patients with AMI during a two-year follow-up period.
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1. Introduction
Even though there is some debate on the efficacy of ß-blockers (BB) in patients with acute
myocardial infarction (AMI) [1–3], oral BB is being prescribed in patients with AMI and reduced left
ventricular ejection fraction (LVEF) to decrease mortality and major adverse cardiac events (MACE)
according to the recommendations of current guidelines in the absence of contraindications [4–7].
For the same reason, renin–angiotensin system inhibitors (RASI) are being prescribed in patients with
AMI and reduced LVEF [4–7]. Additionally, some recent reports have suggested that BB and RASI
are effective in patients with preserved LVEF [8,9] Hence, among the many patients with AMI who
do not have a reduced LVEF and/or heart failure (HF), oral BB is administered in real-world practice.
However, BB has been known to increase the risk of severe or prolonged hypoglycemia and delay
recovery from hypoglycemia in patients with diabetes [10]. Currently, the presence or absence or the
degree of adverse cardiovascular risk associated with BB use in patients with diabetes is debatable [11,12].
Prediabetes is also associated with cardiovascular morbidity and mortality [13,14], and the number of
individuals with prediabetes could exceed 470 million by 2030 [15]. However, despite their important
effects on cardiovascular disease, research concerning the long-term clinical outcomes of prediabetes in
patients with AMI is more limited than those in diabetes. In Korea, more than 40% of AMI patients
received BB + RASI therapy after drug-eluting stent (DES) implantation [16]. Therefore, we investigated
the two-year major clinical outcomes between prediabetes and diabetes mellitus (DM) in patients with
AMI who received BB + RASI therapy after successful percutaneous coronary intervention (PCI) with
newer-generation DES to estimate the clinical effects of prediabetes in such patients.
2. Materials
2.1. Study Design and Population
In the current study, we attempted to confine to type 2 DM (T2DM) patients for diabetes.
We considered T2DM based on a previous study [17], which included patients from the Korea AMI
Registry (KAMIR). Hence, a total of 21,343 AMI patients aged ≥30 years at the onset of diabetes who
underwent successful PCI using newer-generation DESs from November 2005 to June 2015 in the
KAMIR [18] were evaluated. The types of newer-generation DESs are given in Table 1. KAMIR [18]
was designed to capture real-world treatment practices and the short- and long-term outcomes of AMI
patients, evaluate the current epidemiology and analyze the prognostic factors of AMI, and improve
the long-term prognosis of individual patients. Eligible patients were ≥18 years of age at the time
of hospital admission. Patients with incomplete laboratory results, including unidentified results
of blood hemoglobin A1c and blood glucose (n = 8314, 39.0%), patients who were lost to follow-up
(n = 1067, 5.0%), and patients who received BB (n = 1423, 6.7%) or RASI alone (n = 1073, 5.0%),
were excluded. After exclusion, a total of 9466 patients with AMI who underwent successful PCI using
newer-generation DES were included. The patients were classified into normoglycemia (n = 2460,
26.0%), prediabetes (n = 2907, 30.7%), and diabetes (n = 4099, 43.3%) groups. These patients were
divided into six groups according to their glycemic status and the presence or absence of BB + RASI
therapy on admission: normoglycemia (BB + RASI users (n = 2217, group A1) and BB + RASI nonusers
(n = 243, group A2)), prediabetes (BB + RASI users (n = 2601, group B1) and BB + RASI nonusers
(n = 306, group B2)), and diabetes (BB + RASI users (n = 3682, group C1) and BB + RASI nonusers
(n = 417, group C2)) (Figure 1, Table 1, Table S1). All 9466 patients finished a two-year clinical follow-up
through face-to-face interviews, phone calls, or medical chart reviews. All clinical events were
evaluated by an independent event adjudicating committee. The processes of event adjudication have
been described in a previous publication of the KAMIR investigators [18]. This was a nonrandomized,
multicenter, observational retrospective cohort study. The ethics committee at each participating center
approved the study protocol, and all participants provided informed consent before inclusion in the
study. The study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki.
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Table 1. Baseline characteristics of BB + RASI users.
Variables
Normoglycemia (Group
A1, n = 2217)
Prediabetes (Group
B1, n = 2601)
Diabetes (Group











Male, n (%) 1803 (81.3) 1995 (76.7) 2588 (70.3) <0.001 <0.001 <0.001 <0.001
Age (years) 60.4 ± 13.0 62.6 ± 12.4 63.7 ± 11.5 <0.001 <0.001 <0.001 <0.001
LVEF (%) 53.2 ± 10.3 53.2 ± 10.4 51.7 ± 11.3 0.968 <0.001 <0.001 <0.001
≤40%, n (%) 182 (8.2) 231 (8.9) 492 (13.4) 0.409 <0.001 <0.001 <0.001
BMI (kg/m2) 23.9 ± 3.1 24.4 ± 3.2 24.5 ± 3.2 <0.001 <0.001 0.212 <0.001
SBP (mmHg) 134.1 ± 27.7 131.6 ± 27.6 132.8 ± 27.9 0.002 0.095 0.090 0.009
DBP (mmHg) 82.3 ± 16.6 80.2 ± 16.5 79.7 ± 16.2 <0.001 <0.001 0.212 <0.001
STEMI, n (%) 1346 (60.7) 1578 (60.7) 1952 (53.0) 0.975 <0.001 <0.001 <0.001
Primary PCI, n (%) 1303 (96.8) 1530 (97.0) 1884 (96.5) 0.813 0.651 0.464 0.754
NSTEMI, n (%) 871 (39.3) 1023(39.3) 1730 (47.0) 0.975 <0.001 <0.001 <0.001
PCI within 24 h 774 (88.9) 887(86.7) 1480 (85.5) 0.154 0.019 0.398 0.064
Hypertension, n (%) 930(41.9) 1163 (44.7) 2210 (60.0) 0.054 <0.001 <0.001 <0.001
Dyslipidemia, n (%) 192(8.7) 294 (11.3) 529 (14.4) 0.002 <0.001 <0.001 <0.001
Previous MI, n (%) 6 (2.9) 55 (2.1) 166 (4.5) 0.085 0.002 <0.001 <0.001
Previous PCI, n (%) 84 (3.8) 117 (4.5) 277 (7.5) 0.220 <0.001 <0.001 <0.001
Previous CABG, n (%) 5 (0.2) 3 (0.1) 22 (0.6) 0.483 0.046 0.002 0.003
Previous CVA, n (%) 97 (4.4) 123 (4.7) 275 (7.5) 0.580 <0.001 <0.001 <0.001
Previous HF, n (%) 9 (0.4) 17 (0.7) 44 (1.2) 0.324 0.002 0.036 0.003
Current smokers, n (%) 1028 (46.4) 122 (47.2) 1464 (39.8) 0.559 <0.001 <0.001 <0.001
Peak CK-MB (mg/dL) 134.4 ± 208.2 142.0 ± 205.6 101.2 ± 137.9 0.204 <0.001 <0.001 <0.001
Peak troponin-I (ng/mL) 46.6 ± 81.5 49.8 ± 138.4 45.6 ± 144.8 0.381 0.751 0.296 0.515
Blood glucose (mg/dL) 136.6 ± 49.9 146.5 ± 45.7 222.8 ± 96.3 <0.001 <0.001 <0.001 <0.001
Hemoglobin A1c (%) 5.33 ± 0.43 5.96 ± 0.21 7.81 ± 2.87 <0.001 <0.001 <0.001 <0.001
NT-ProBNP (pg/mL) 264.0 (62.0–1225.0) 223.0 (56.0–919.0) 348.5 (78.8–1750.5) 0.215 <0.001 <0.001 <0.001
hs-CRP (mg/dL) 5.7 ± 31.2 8.9 ± 55.9 9.1 ± 43.6 0.030 0.003 0.888 0.047
Serum creatinine (mg/L) 0.99 ± 0.87 1.02 ± 1.02 1.13 ± 1.08 0.379 <0.001 <0.001 <0.001
eGFR (mL/min/1.73 m2) 92.1 ± 33.9 90.4 ± 37.3 86.6 ± 44.6 0.107 <0.001 <0.001 <0.001
<60 mL/min/1.73 m2 242 (10.9) 349 (13.4) 779 (21.2) 0.009 <0.001 <0.001 <0.001
Total cholesterol (mg/dL) 183.0 ± 40.1 190.6 ± 42.9 180.6 ± 48.9 <0.001 0.050 <0.001 <0.001




A1, n = 2217)
Prediabetes (Group
B1, n = 2601)
Diabetes (Group











Triglyceride (mg/L) 120.8 ± 91.8 138.3 ± 111.8 154.5 ± 138.6 <0.001 <0.001 <0.001 <0.001
HDL cholesterol (mg/L) 44.5 ± 144 43.2 ± 15.8 42.0 ± 14.2 0.153 <0.001 <0.001 <0.001
LDL cholesterol (mg/L) 116.4 ± 36.1 122.6 ± 49.3 111.4 ± 38.8 <0.001 <0.001 <0.001 <0.001
Diabetes management
Diet 314 (8.5)




Aspirin, n (%) 2205 (99.5) 2587 (99.5) 3669 (99.6) 0.989 0.281 0.269 0.451
Clopidogrel, n (%) 1774 (80.0) 2229 (85.7) 3166 (86.0) <0.001 <0.001 0.747 <0.001
Ticagrelor, n (%) 281 (12.7) 235 (9.0) 282 (7.7) <0.001 <0.001 0.051 <0.001
Prasugrel, n (%) 147 (6.6) 122 (4.7) 194 (5.3) 0.003 0.030 0.319 0.010
Cilostazole, n (%) 304 (13.7) 495 (19.0) 749 (20.3) <0.001 <0.001 0.210 <0.001
CCBs, n (%) 86 (3.9) 96 (3.7) 219 (5.9) 0.733 0.001 <0.001 <0.001
Lipid-lowering agents 2267 (93.7) 2431 (93.5) 3320 (90.2) 0.755 <0.001 <0.001 <0.001
IRA
Left main, n (%) 37 (1.7) 31 (1.2) 65 (1.8) 0.178 0.837 0.076 0.117
LAD, n (%) 1152 (52.0) 1337 (51.4) 1707 (46.4) 0.699 <0.001 <0.001 <0.001
LCx, n (%) 371 (16.7) 439 (16.9) 638 (17.3) 0.894 0.568 0.642 0.815
RCA, n (%) 657 (29.6) 794 (30.5) 1272 (34.5) 0.501 <0.001 0.001 <0.001
Treated vessel
Left main, n (%) 55 (2.5) 62 (2.4) 108 (2.9) 0.827 0.326 0.207 0.349
LAD, n (%) 1342 (60.5) 1577 (60.6) 2155 (58.5) 0.945 0.129 0.095 0.159
LCx, n (%) 563 (25.4) 666 (25.6) 1039 (28.2) 0.867 0.018 0.022 0.020
RCA, n (%) 783 (35.3) 961 (36.9) 1560 (42.4) 0.241 <0.001 <0.001 <0.001
ACC/AHA lesion type
Type B1, n (%) 294 (13.3) 352 (13.5) 458 (12.4) 0.782 0.359 0.202 0.404
Type B2, n (%) 767 (34.6) 853 (32.8) 1284 (34.9) 0.187 0.829 0.087 0.205
Type C, n (%) 983 (44.3) 1145 (44.0) 1635 (44.4) 0.825 0.961 0.763 0.953




A1, n = 2217)
Prediabetes (Group
B1, n = 2601)
Diabetes (Group












1-vessel, n (%) 1219 (55.0) 1396 (53.7) 1605 (43.6) 0.384 <0.001 <0.001 <0.001
2-vessel, n (%) 655 (29.5) 785 (30.2) 1215 (33.0) 0.631 0.006 0.018 0.008
≥3-vessel, n (%) 343 (15.5) 420 (16.1) 862 (23.4) 0.552 <0.001 <0.001 <0.001
IVUS 452 (20.4) 617 (23.7) 766 (20.8) 0.006 0.702 0.007 0.006
OCT 16 (0.7) 27 (1.0) 24 (0.7) 0.245 0.746 0.093 0.215
FFR 25 (1.1) 36 (1.4) 54 (1.5) 0.428 0.294 0.830 0.544
Drug-eluting stents
ZES, n (%) 696 (31.4) 861 (33.1) 1217 (33.1) 0.861 0.187 0.967 0.349
EES, n (%) 1108 (50.0) 1322 (50.8) 1871 (50.8) 0.557 0.533 0.993 0.792
BES, n (%) 368 (16.6) 360 (13.8) 500 (13.6) 0.008 0.002 0.767 0.003
Others, n (%) 45 (2.0) 58 (2.2) 94 (2.6) 0.690 0.215 0.453 0.406
Stent diameter (mm) 3.16 ± 0.42 3.16 ± 0.42 3.10 ± 0.42 0.686 <0.001 <0.001 <0.001
Stent length (mm) 27.5 ± 11.7 26.8 ± 11.2 27.5 ± 11.9 0.028 0.863 0.023 0.040
Number of stents 1.42 ± 0.74 1.46 ± 0.78 1.55 ± 0.82 0.029 <0.001 <0.001 <0.001
Values are mean ± SD or numbers and percentages or median (quartiles 1–3). The p values for continuous data obtained from the analysis of variance. The p values for categorical data from
chi-square or Fisher’s exact test. LVEF, left ventricular ejection fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; STEMI, ST-elevation myocardial
infarction; NSTEMI, non-STEMI; PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass graft; CVA, cerebrovascular accident; HF, heart failure;
CK-MB, creatine kinase myocardial band; NT-ProBNP, N-terminal probrain natriuretic peptide; hs-CRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; CCBs, calcium channel blockers; IRA, infarct-related artery; LAD, left anterior descending coronary artery; LCx, left circumflex
coronary artery; RCA, right coronary artery; CAD, coronary artery disease; ACC/AHA, American College of Cardiology/American Heart Association; IVUS, intravascular ultrasound; OCT,
optical coherence tomography; FFR, fractional flow reserve; ZES, zotarolimus-eluting stent; EES, everolimus-eluting stent; BES, biolimus-eluting stent.
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2.2. Percutaneous Coronary Intervention Procedure and Medical Treatment
Diagnostic coronary angiography and PCI were done through either the femoral or radial artery
using standard techniques [19]. Aspirin (200–300 mg) and clopidogrel (300–600 mg) were administered
before PCI, Alternatively, ticagrelor (180 mg) or prasugrel (60 mg) was administered. After PCI,
the total duration of dual antiplatelet therapy (DAPT, a combination of aspirin (100 mg/day) with
clopidogrel (75 mg/day), ticagrelor (90 mg twice daily), or prasugrel (5–10 mg/day)) was recommended
for >12 months. Moreover, in this registry, there were no operator restrictions for performing PCI.
2.3. Study Definitions and Clinical Outcomes
AMI was defined according to current guidelines [4,5]. A successful PCI was defined as a residual
stenosis <30% and thrombolysis in myocardial infarction grade 3 flow for the infarct-related artery
(IRA) after the procedure. Glycemic categories were determined based on the glycosylated hemoglobin
(HbA1c), fasting plasma glucose (FPG), and random plasma glucose (RPG) levels of the patients at
the index hospitalization as well as their medical history. Diabetes was defined as either known
diabetes for which patients received medical treatment (insulin or antidiabetics) or newly diagnosed
diabetes defined as an HbA1c level ≥6.5%, FPG ≥126 mg/dL (7.0 mmol/L), and/or RPG ≥200 mg/dL
(11.1 mmol/L) according to the American Diabetes Association clinical practice recommendations [20].
Prediabetes was defined as an HbA1c of 5.7–6.4% and an FPG of 100–125 mg/dL (5.6–6.9 mmol/L) [20].
Furthermore, the estimated glomerular filtration rate (eGFR) was calculated using the Modification of
Diet in Renal Disease (MDRD) study equation [21]. The primary clinical endpoint of this study was
the occurrence of MACEs defined as all-cause death, recurrent myocardial infarction (Re-MI), or any
repeat revascularization. The secondary endpoint was the cumulative incidence of hospitalization for
HF (HHF) during a two-year follow-up period. All-cause death was classified as cardiac death (CD) or
non-CD. Any repeat revascularization was composed of target lesion revascularization, target vessel
revascularization (TVR), and non-TVR.
2.4. Statistical Analysis
For continuous variables, differences among the three groups were evaluated using an analysis of
variance or the Jonckheere–Terpstra test, while post hoc analysis was performed using the Hochberg
test or Dunnett T3 test; the data are expressed as the mean ± standard deviation. For categorical
variables, intergroup differences were analyzed using a χ2 test or Fisher’s exact test, as appropriate.
Data are expressed as counts and percentages. Various clinical outcomes were estimated using the
Kaplan–Meier method, and intergroup differences were compared using a log-rank test. To determine
meaningful variables, all variables with p < 0.1 were included in the univariate analysis. After univariate
analysis, variables with p < 0.001 and known conventional risk factors of poor outcomes in the AMI
population were considered potential confounding factors and were entered into the multivariate
analysis. These variables included the following: male, age, LVEF (≤40%), body mass index,
diastolic blood pressure, ST-elevation myocardial infarction (STEMI), hypertension, dyslipidemia,
previous MI, previous PCI, previous cerebrovascular accidents, current smokers, creatine kinase
myocardial band (CK-MB), N-terminal pro-brain natriuretic peptide (NT-ProBNP), serum creatinine,
eGFR (<60 mL/min/1.73 m2), total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, clopidogrel, ticagrelor, cilostazole, calcium channel blockers,
lipid-lowering agents, left anterior descending coronary artery (LAD; IRA), right coronary artery (RCA;
IRA and treated vessel), one-vessel disease, ≥3-vessel disease, stent diameter, and number of stents
(Table 2). In the same way, the comparisons of major clinical outcomes between BB + RASI users and
nonusers in all three groups (normoglycemia, prediabetes, and diabetes) were performed as shown in
Table 3. For all analyses, two-sided p < 0.05 were considered statistically significant. All statistical
analyses were performed using SPSS version 20 (IBM; Armonk, NY, USA).
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Table 2. Comparison of clinical outcomes according to the presence or absence of BB + RASI therapy at two-year follow-up.
BB + RASI (+)
Group A1 Group B1 Unadjusted Adjusted a
Normoglycemia (n = 2217) Prediabetes (n = 2601) Log-Rank HR (95% CI) p value HR (95% CI) p value
MACEs 109 (5.5) 166 (6.8) 0.068 1.252 (0.983–1.594) 0.069 1.464 (1.022–2.096) 0.038
All-cause death 30 (1.5) 50 (2.0) 0.164 1.377 (0.876–2.166) 0.166 1.331 (0.647–2.040) 0.438
Cardiac death 20 (1.0) 38 (1.5) 0.094 1.582 (0.921–2.719) 0.097 1.987 (0.791–4.988) 0.144
Re-MI 30 (1.5) 40 (1.6) 0.691 1.101 (0.686–1.767) 0.691 1.288 (0.638–1.998) 0.479
Any repeat revascularization 58 (3.0) 83 (3.5) 0.376 1.164 (0.832–1.627) 0.376 1.583 (0.979–2.558) 0.061
Hospitalization for HF 17 (0.8) 27 (1.0) 0.325 1.355 (0.738–2.485) 0.327 1.129 (0.501–2.348) 0.769
Group A1 Group C1 Unadjusted Adjusted a
Normoglycemia (n = 2217) Diabetes (n = 3682) Log-Rank HR (95% CI) p value HR (95% CI) p value
MACEs 109 (5.5) 305 (9.0) <0.001 1.636 (1.315–2.036) <0.001 1.587 (1.139–2.012) 0.006
All-cause death 30 (1.5) 117 (3.4) <0.001 2.282 (1.528–3.409) <0.001 1.579 (0.857–2.010) 0.143
Cardiac death 20 (1.0) 79 (2.3) 0.001 2.321 (1.421–3.792) 0.001 1.550 (0.698–1.992) 0.282
Re-MI 30 (1.5) 86 (2.6) 0.016 1.661 (1.096–2.517) 0.017 2.275 (1.218–4.247) 0.010
Any repeat revascularization 58 (3.0) 148 (4.5) 0.010 1.488 (1.098–2.015) 0.010 1.532 (0.973–2.412) 0.065
Hospitalization for HF 17 (0.8) 62 (1.7) 0.003 2.203 (1.288–3.768) 0.004 1.625 (0.806–3.275) 0.175
Group B1 Group C1 Unadjusted Adjusted a
Prediabetes (n = 2601) Diabetes (n = 3682) Log-Rank HR (95% CI) p value HR (95% CI) p value
MACEs 166 (6.8) 305 (9.0) 0.005 1.313 (1.087–1.587) 0.005 1.127 (0.860–1.477) 0.387
All-cause death 50 (2.0) 117 (3.4) 0.002 1.667 (1.197–2.321) 0.002 1.391 (0.808–2.307) 0.234
Cardiac death 38 (1.5) 79 (2.3) 0.046 1.479 (1.004–2.177) 0.048 1.142 (0.608–2.144) 0.679
Re-MI 40 (1.6) 86 (2.6) 0.024 1.536 (1.056–2.235) 0.025 1.660 (1.000–2.755) 0.020
Any repeat revascularization 83 (3.5) 148 (4.5) 0.071 1.280 (0.978–1.674) 0.072 1.004 (0.698–1.443) 0.983
Hospitalization for HF 27 (1.0) 62 (1.7) 0.033 1.627 (1.035–2.556) 0.035 1.428 (0.760–2.685) 0.268
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Table 2. Cont.
BB + RASI (−)
Group A2 Group B2 Unadjusted Adjusted b
Normoglycemia (n = 243) Prediabetes (n = 306) Log-Rank HR (95% CI) p value HR (95% CI) p value
MACEs 38 (16.2) 61 (20.6) 0.228 1.281 (1.854–1.921) 0.231 1.544 (0.942–2.532) 0.085
All-cause death 31 (12.8) 55 (18.5) 0.122 1.411 (0.909–2.192) 0.125 1.518 (0.872–2.642) 0.140
Cardiac death 26 (10.8) 48 (16.1) 0.112 1.467 (0.911–2.365) 0.115 1.527 (0.830–2.810) 0.173
Re-MI 5 (2.2) 7 (2.6) 0.831 1.133 (0.359–3.569) 0.832 2.272 (0.522–9.882) 0.274
Any repeat revascularization 7 (3.7) 17 (7.1) 0.139 1.921 (0.797–4.633) 0.146 1.569 (0.419–3.878) 0.504
Hospitalization for HF 6 (2.5) 12 (3.9) 0.343 1.600 (0.600–4.263) 0.347 2.507 (0.786–7.992) 0.120
Group A2 Group C2 Unadjusted Adjusted b
Normoglycemia (n = 243) Diabetes (n = 417) Log-Rank HR (95% CI) p value HR (95% CI) p value
MACEs 38 (16.2) 119 (29.1) <0.001 1.924 (1.335–2.772) <0.001 1.708 (1.126–2.590) 0.012
All-cause death 31 (12.8) 102 (24.8) 0.001 2.005 (1.341–2.997) 0.001 1.759 (1.109–2.788) 0.016
Cardiac death 26 (10.8) 87 (21.2) 0.001 2.033 (1.312–3.151) 0.002 1.844 (1.106–3.075) 0.019
Re-MI 5 (2.2) 15 (4.6) 0.212 1.885 (0.685–5.187) 0.220 1.573 (0.503–4.923) 0.436
Any repeat revascularization 7 (3.7) 27 (8.6) 0.035 2.378 (1.036–5.462) 0.041 2.044 (0.828–5.045) 0.121
Hospitalization for HF 6 (2.5) 16 (3.8) 0.347 1.562 (0.611–3.993) 0.351 1.227 (0.427–3.821) 0.662
Group B2 Group C2 Unadjusted Adjusted b
Prediabetes (n = 306) Diabetes (n = 417) Log-Rank HR × (95% CI) p value HR (95% CI) p value
MACEs 61 (20.6) 119 (29.1) 0.009 1.501 (1.102–2.044) 0.010 1.301 (0.913–1.854) 0.146
All-cause death 55 (18.5) 102 (24.8) 0.034 1.421 (1.024–1.972) 0.036 1.225 (0.839–1.789) 0.293
Cardiac death 48 (16.1) 87 (21.2) 0.069 1.384 (0.973–1.969) 0.071 1.232 (0.814–1.863) 0.323
Re-MI 7 (2.6) 15 (4.6) 0.256 1.673 (0.682–4.103) 0.261 1.564 (0.601–3.666) 0.325
Any repeat revascularization 17 (7.1) 27 (8.6) 0.475 1.247 (0.680–2.288) 0.476 1.077 (0.540–2.148) 0.833
Hospitalization for HF 12 (3.9) 16 (3.8) 0.951 1.024 (0.484–2.164) 0.951 1.404 (0.592–3.331) 0.441
a Adjusted by male, age, LVEF (≤40%), BMI, DBP, STEMI, hypertension, dyslipidemia, previous MI, previous PCI, previous CVA, current smokers, CK-MB, NT-ProBNP, serum creatinine,
eGFR (<60 mL/min/1.73 m2), total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, clopidogrel, ticagrelor, cilostazole, CCBs, lipid-lowering agents, LAD (IRA), RCA (IRA and
treated vessel), one-vessel disease, ≥3-vessel disease, stent diameter, and number of stents. b Adjusted by hypertension, current smokers, NT-ProBNP, eGFR (<60 mL/min/1.73 m2),
triglyceride, LDL cholesterol, and one-vessel disease. BB, ß-blockers; HF, heart failure; LVEF, left ventricular ejection fraction; BMI, body mass index; DBP, diastolic blood pressure; STEMI,
ST-elevation myocardial infarction; NSTEMI, non-STEMI; PCI, percutaneous coronary intervention; CVA, cerebrovascular accident; CK-MB, creatine kinase myocardial band; NT-ProBNP,
N-terminal pro-brain natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CCBs, calcium channel blockers; IRA,
infarct-related artery; LAD, left anterior descending coronary artery; RCA, right coronary artery; HR, hazard ratio; CI, confidence interval.
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Table 3. Comparison of clinical outcomes between BB + RASI users and nonusers at two-year follow-up.
Outcomes BB + RASI (+) A1 (n = 2217) BB + RASI (−) A2 (n = 243) Log-Rank
Unadjusted Adjusted a
HR (95% CI) p Value HR (95% CI) p value
Normoglycemia
MACEs 109 (5.5) 38 (16.2) <0.001 3.484 (2.408–5.041) <0.001 3.033 (1.654–5.562) <0.001
All-cause death 30 (1.5) 31 (12.8) <0.001 10.16 (6.146–16.78) <0.001 6.495 (2.820–14.96) <0.001
Cardiac death 20 (1.0) 26 (10.8) <0.001 12.63 (7.051–22.64) <0.001 8.848 (3.121–19.09) <0.001
Re-MI 30 (1.5) 5 (2.2) 0.299 1.643 (0.637–4.235) 0.304 1.702 (0.458–6.327) 0.427
Any revascularization 58 (3.0) 7 (3.7) 0.579 1.248 (0.570–2.734) 0.580 1.438 (0.298–6.945) 0.651
Hospitalization for HF 17 (0.8) 6 (2.5) 0.008 3.256 (1.284–8.259) 0.013 3.242 (1.279–7.525) 0.014
Outcomes BB + RASI × (+) B1 (n = 2601) BB + RASI (−) B2 (n = 306) Log-Rank
Unadjusted Adjusted b
HR (95% CI) p value HR (95% CI) p value
Prediabetes
MACEs 166 (6.8) 61 (20.6) <0.001 3.549 (2.646–4.761) <0.001 3.450 (2.288–4.202) <0.001
All-cause death 50 (2.0) 55 (18.5) <0.001 10.34 (7.048–15.17) <0.001 9.197 (5.246–14.82) <0.001
Cardiac death 38 (1.5) 48 (16.1) <0.001 11.68 (7.627–17.88) <0.001 10.20 (5.322–16.54) <0.001
Re-MI 40 (1.6) 7 (2.6) 0.203 1.676 (0.751–3.743) 0.208 1.891 (0.666–4.972) 0.175
Any revascularization 83 (3.5) 17 (7.1) 0.005 2.073 (1.230–3.493) 0.006 2.134 (1.314–4.038) 0.005
Hospitalization for HF 27 (1.0) 12 (3.9) <0.001 3.855 (1.953–7.610) <0.001 3.487 (1.556–6.234) 0.011
Outcomes BB + RASI (+) C1 (n = 3862) BB + RASI (−) C2 (n = 417) Log-Rank
Unadjusted Adjusted c
HR (95% CI) p value HR (95% CI) p value
Diabetes
MACEs 305 (9.0) 119 (29.1) <0.001 4.142 (3.351–5.121) <0.001 4.265 (2.937–6.193) <0.001
All-cause death 117 (3.4) 102 (24.8) <0.001 8.959 (6.868–11.69) <0.001 7.227 (4.374–10.94) <0.001
Cardiac death 79 (2.3) 87 (21.2) <0.001 11.06 (8.150–15.00) <0.001 9.005 (5.156–13.73) <0.001
Re-MI 86 (2.6) 15 (4.6) 0.022 1.881 (1.087–3.256) 0.024 2.957 (1.380–6.336) 0.005
Any revascularization 148 (4.5) 27 (8.6) 0.001 2.020 (1.340–3.045) 0.001 4.360 (2.344–8.108) <0.001
Hospitalization for HF 62 (1.7) 16 (3.8) 0.002 2.323 (1.341–4.024) 0.003 2.015 (1.035–3.156) 0.031
a Adjusted by age, LVEF (≤40%), SBP, DBP, CK-MB, NT-ProBNP, eGFR (<60 mL/min/1.73 m2), total cholesterol, triglyceride, HDL cholesterol, aspirin, and lipid-lowering agents.
b Adjusted by age, LVEF (≤40%), BMI, SBP, DBP, previous HF, triglyceride, aspirin, CCBs, and lipid-lowering agents. c Adjusted by age, LVEF (≤40%), SBP, DBP, peak CK-MB, blood glucose,
NT-ProBNP, hs-CRP, serum creatinine, eGFR (<60 mL/min/1.73 m2), aspirin, cilostazole, lipid-lowering agents, and ACC/AHA type B2 lesion. BB, ß-blockers; RASI, renin–angiotensin
system inhibitors; HR, hazard ratio; CI, confidence interval; MACEs, major adverse cardiac events; Re-MI, recurrent myocardial infarction; HF, heart failure; LVEF, left ventricular ejection
fraction; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; CK-MB, creatine kinase myocardial band; NT-ProBNP, N-terminal probrain natriuretic peptide;
hs-CRP, high sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; CCBs, calcium channel blockers; ACC/AHA, American College of
Cardiology/American Heart Association.
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Figure 1. Flow chart showing the patient selection process for the study. AMI, acute myocardial
infarction; PCI, percutaneous coronary intervention; DESs, drug-eluting stents; KAMIR, Korea AMI
Registry; BB, ß-blocker; RASI, renin–angiotensin system inhibitor.
3. Results
3.1. Baseline Characteristics
The mean LVEF value of this study population was more than 50% (Table 1). Group A1
(normoglycemia and BB + RASI users) had the most men, the highest number of one-vessel disease;
the highest systolic and diastolic blood pressure, peak CK-MB, and eGFR; the highest prescription rate
of ticagrelor, angiotensin-converting enzyme inhibitors (ACEIs), prasugrel, and lipid-lowering agents;
the highest LAD as IRA; and the largest diameter of deployed stents. Group B1 (prediabetes and
BB + RASI users) had the highest number of current smokers; the highest levels of total and low-density
lipoprotein cholesterol; and the highest use of intravascular ultrasound. Group C1 (diabetes and
BB + RASI users) had the highest number of non-STEMI (NSTEMI), multivessel disease, and RCA
as IRA and treated vessel; the highest total number of deployed stents; the oldest mean patient age
of all groups; the lowest level of eGFR and high-density lipoprotein cholesterol; and the highest
number of risk factors for coronary heart disease (e.g., hypertension, dyslipidemia, previous history
of MI, PCI, coronary artery bypass graft, stroke, and HF), as expected. Moreover, the highest levels
of NT-ProBNP, high sensitivity C-reactive protein, and triglycerides were also observed in group
C1. Baseline characteristics of the total study population and BB + RASI nonusers are shown in
Tables S1 and S2.
3.2. Clinical Outcomes
Tables 2 and 3 and Figure 2 show the cumulative incidences of major clinical outcomes during
the two-year follow-up period. As can be seen in Table 2, the cumulative incidences of MACEs
(adjusted hazard ratio (aHR): 1.127; 95% confidence interval (CI): 0.860–1.477; p = 0.387), all-cause death,
CD, any repeat revascularization, and HHF (aHR: 1.428; 95% CI: 0.760-2.685; p = 0.268) were similar
between group B1 (prediabetes and BB + RASI users) and C1 (diabetes and BB + RASI users). However,
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the cumulative incidence of Re-MI was higher in group C1 than group B1 (aHR: 1.660; 95% CI:
1.000–2.755; p = 0.020). The cumulative incidence of MACEs (aHR: 1.464; 95% CI: 1.022–2.096; p = 0.038)
was higher in group B1 than in group A1 (normoglycemia and BB + RASI users). The cumulative
incidences of MACEs (aHR: 1.587; 95% CI: 1.139–2.012; p = 0.006) and Re-MI (aHR: 2.275; 95% CI:
1.218–4.247; p = 0.010) were significantly higher in group C1 than in group A1. In BB + RASI nonusers,
the cumulative incidences of MACEs (aHR: 1.708; 95% CI: 1.126-2.590; p = 0.012), all-cause death
(aHR: 1.759; 95% CI: 1.109–2.788; p = 0.016), and CD (aHR: 1.844; 95% CI: 1.106–3.075; p = 0.019)
were higher in group C2 (diabetes) than in group A2 (normoglycemia). In Table 3, in all three groups
(normoglycemia, prediabetes, and diabetes), BB + RASI therapy reduced the cumulative incidences
of MACEs, all-cause death, CD, and HHF. Additionally, in the prediabetes group, BB + RASI users
showed lower cumulative incidence of any repeat revascularization than that of BB + RASI nonusers.
In the diabetes group, BB + RASI users showed lower cumulative incidences of Re-MI and any repeat
revascularization than those of BB + RASI nonusers. Independent predictors for MACEs and HHF in
BB + RASI users at two-year follow-up are shown in Table S3. Male sex, STEMI, decreased LVEF (<40%),
lipid-lowering agents, decreased eGFR (<60 mL/min/1.73 m2),≥3-vessel disease, the use of intravascular
ultrasound (IVUS), and ≥30 mm length of the deployed stent were meaningful independent predictors
for MACEs. Moreover, old age (≥65 years), STEMI, decreased LVEF, decreased eGFR, and ACC/AHA
type B2/C lesions were independent predictors for HHF in this study.
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BB, ß-blockers; RASI, renin-angiotensin system inhibitor; NG, normoglycemia; Pre-DM, prediabetes,
DM, diabetes; MACES, major adverse cardiac events; HHF, hospitalization for heart failure; Re-MI,
recurrent myocardial infarction.
4. Dis ssion
Because fewer data are available in patients with prediabetes concerning their long-term prognosis,
the authors wanted to examine whether or not long-term outcome in patients after AMI and prediabetes
or diabetes who received BB and RASI and were treated with newer-generation drug-eluting stents
would show differences in clinical outcomes after two years.
In this retrospective observational registry study, our analysis showed the following findings after
BB + RASI therapy: (1) The cumulative incidences of primary and secondary clinical outcomes were
similar between the prediabetes and diabetes groups. However, the cumulative incidence of Re-MI was
higher in the diabetes group than in the prediabetes group. (2) The cumulative incidence of MACEs of
the prediabetes group and the cumulative incidences of MACEs and Re-MI of the diabetes group were
higher than in the normoglycemia group. (3) In all three different glycemic groups (normoglycemia,
prediabetes, and diabetes), the cumulative incidences of MACEs, all-cause death, CD, and HHF were
lower compared to those of who did not receive BB + RASI therapy. (4) The cumulative incidence of
any repeat revascularization of the prediabetes group and Re-MI and any repeat revascularization of
the diabetes group were also decreased after BB + RASI therapy than those of patients who did not
receive BB + RASI therapy. (5) Old age, STEMI, decreased LVEF, and decreased eGFR were common
independent predictors of both MACEs and HHF.
According to the European Society of Cardiology (ESC) guidelines [5], the use of BB in patients
with STEMI has recently decreased from class I to class IIa. oreover, some studies have raised
questions regarding the mortality risk reduction capability of BB in patients with coronary artery
disease [22,23]. However, BB has been considered as a core drug for secondary prevention in patients
with coronary and other atherosclerotic vascular disease, including patients ith AMI and T2DM,
in the absence of contraindications [24,25]. RASI has been shown to have diverse beneficial effects on
cardiovascular outcomes through the enhancement of endothelial function, cardiovascular remodeling,
and progression of atherosclerosis [26,27]. Recent [12] and previous reports [28] have suggested that
BB + RASI therapy is ore effective for patients after AMI than BB or RASI alone to reduce mortality.
Therefore, in our study, we compared the clinical outcomes in patients with AMI who received or
did not receive BB + RASI therapy and observed that BB + RASI therapy reduced the cumulative
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incidences of MACEs, all-cause death, CD, and HHF compared to BB + RASI nonusers regardless of
the glycemic status. These beneficial effects of BB + RASI therapy were more prominent during the
first three months after discharge (Figure 2). In their study of 2679 patients with AMI and preserved
LVEF, Puymirat et al. [29] demonstrated that 30-day mortality was significantly lower in patients who
received BB during the first 48 h after admission compared to those who did not (HR: 0.46; 95% CI:
0.26–0.82; p = 0.008). Regarding more recently published results [30], RASI has also been shown to
have early mortality reduction benefit in patients with diabetes and prediabetes.
In the Hoorn study [31], the risk of a recurrent cardiovascular event was similar between the
normoglycemia and prediabetes groups. However, individuals with diabetes had an increased risk of
recurrent cardiovascular events compared to individuals with normoglycemia during a median 4.1 years
of follow-up after the first event. According to a recent report [30], after adjustment, the cumulative
incidence of Re-MI of the diabetes group in RASI users was significantly higher than that of the
prediabetes group (aHR: 1.999; 95% CI: 1.153–3.467; p = 0.014). Deedwania et al. [32] suggested that
the association between diabetes and Re-MI may be a direct effect of diabetes. Hyperglycemia has
been linked to an increase in plasma renin activity with RAS activation, which is known to impair
insulin signaling [33]. Hyperglycemia, insulin resistance, and advanced glycation end-products
can contribute to vascular inflammation and endothelial dysfunction in patients with diabetes [34].
Increased platelet activation, the presence of a chronic hypercoagulable state, and impaired fibrinolysis
are also considerable factors in this unfavorable clinical outcome [35].
In the current study, despite the number of patients with decreased LVEF being the highest in the
diabetes group (Table 1, Table S1), the cumulative incidence of HHF was not significantly different
among the three different glycemic groups regardless of the presence or absence of BB + RASI therapy
after adjustment (Table 2). A possible explanation for this result is supported by the current guidelines
that emphasize the beneficial role of BB or RASI in patients with AMI and reduced LVEF [4–7]. Moreover,
these results may be similar to those of the CAPRICORN (Carvedilol Post-Infarct Survival Control
in LV Dysfunction) randomized trial [36], which showed that BB + RASI therapy reduced mortality
in patients with AMI and reduced LVEF (≤40%) with or without HF. Additionally, María et al. [37]
demonstrated that, among hospitalized survivors of AMI, the use of RASI was associated with a lower
risk of follow-up HF in patients with a LVEF≤40% but not in those with a LVEF >40%. As shown in
Table S3, decreased LVEF (<40%) was a significant independent predictor for both MACEs (aHR: 1.634;
95% CI: 1.302–2.018; p < 0.001) and HHF (aHR: 6.923; 95% CI: 4.897–9.832; p < 0.001) in our study.
Even though there are diverse kinds of newly developed antidiabetic drugs and many efforts to
prevent and delay the progression of disease in patients with prediabetes, intensive lifestyle changes
and metformin therapy are the only universally accepted interventions for diabetes prevention [38].
BB and RASI are well-known drugs that can reduce short- and long-term morbidity and mortality in
patients with AMI regardless of their glycemic status. However, current guidelines [4–7] do not suggest
indications or have not shown the effects of these drugs in patients with AMI and prediabetes, and other
reports regarding these comparative results between prediabetes and diabetes in such conditions
have not been reported. Therefore, we believe that the results of this study can provide important
insights for interventional cardiologists concerning the effects of BB + RASI therapy in patients with
AMI and prediabetes and the clinical implication of prediabetes in patients with AMI. In this study,
11,877 patients (55.6%) were excluded due to incomplete laboratory results, including unidentified
results of blood HbA1c and blood glucose, in addition to those excluded due to loss at follow-up
and receiving BB or RASI alone. This appears to be a rather large proportion and can introduce
selection bias if those who did not have HbA1c and blood glucose tests during hospitalization had a
different clinical profile than those who had these tests. As mentioned, the baseline (e.g., sex difference,
proportion of STEMI, degree of LVEF, and renal function) and lesion and procedural characteristic
(e.g., extent of coronary artery disease and length of deployed stent) of the excluded patients could
affect the main results of our study. Moreover, the ratio of three groups (normoglycemia, prediabetes,
and diabetes) of the excluded patients may act as an important determinant of major clinical outcomes.
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Therefore, considering the composition of this study population, caution is needed in interpreting
the results. Even though the size of the study population may be insufficient for conclusion, in this
nationwide, retrospective, observational, multicenter registry analysis, more than 50 community and
teaching hospitals in South Korea participated. However, larger, well-designed randomized controlled
trials are required to confirm these results focusing on newer-generation DESs.
This study has some limitations. First, this study was based on a registry that was voluntary at
each participating center, and the follow-up data were partially incomplete. Hence, the outcomes and
conclusions are subject to the constraints inherent in these types of analyses. Second, the definition
of patients with prediabetes based on their HbA1c levels rather than on an oral glucose tolerance
test may have been a source of bias. Third, this study was based on discharge medications, and the
KAMIR did not include detailed, whole data concerning the prescription doses, long-term adherence,
discontinuation, and drug-related adverse events. The degree of glycemic control of the participants
during the follow-up period was not clearly defined, which may constitute an additional bias.
A majority of patients following AMI, especially with reduced LVEF, receive specific BB and ACEI or
angiotensin II receptor blocker (ARB) and mineralocorticoid inhibitor. There are numerous clinical
trials [36,39–41] with specific drugs in different configurations in patients after MI. However, because
of the above limitations, we could not provide detailed information regarding specific drugs in
different configurations in our enrolled patients. This is another major limitation of this study. Fourth,
another weakness of this study was the lack of information about the BB and RASI drugs used.
Different medicines from these two classes have different impacts on glucose metabolism. Therefore,
it is important to clearly state which drugs/classes of drugs were taken into analysis and to check their
impact on long-term outcomes considering their mechanistic influence on carbohydrate metabolism.
However, because this registry did not include this information, we could not provide meaningful
results concerning the relationship between these two class of drugs and their impact on glucose
metabolism. Additionally, the heterogeneity of applied therapy may influence long-term clinical
outcome of this study. Moreover, it is important to have data on the reason why BB or RASI were not
used in patients in the BB + RASI nonuser group. Unfortunately, this information was not available in
our registry data [42,43]. This point is also a big weakness of this study. Fifth, although we performed
a multivariate analysis to strengthen our results, variables not included in KAMIR may have affected
the study outcomes. Sixth, due to the lack of information concerning the occurrence of hypoglycemia
during BB therapy in KAMIR, we could not provide data related to potential hypoglycemia in BB-treated
patients, and the present analysis will not answer the question of whether or not BB and RASI may be
indicated in patients with normal LVEF post-AMI. Finally, the two-year follow-up period in this study
was relatively short to determine the long-term clinical outcomes of these strategies.
5. Conclusions
In conclusion, in this study, prediabetic and diabetic patients were not different in their outcome
when treated with BB and RASI over two years, but they were certainly both better off than the
corresponding groups without treatment with these established drugs post-AMI. However, the results
should be interpreted with caution due to the lack of details on the adherence and feedback to the
therapy prescribed. Moreover, further well-designed studies are warranted to confirm these results.
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